Form 4: IMMUNIC Director Joerg Neermann Increases Stake with Significant Stock Purchases

IMMUNIC, INC. Director Joerg Neermann has reported the acquisition of 100,000 shares of common stock over two days in early June 2025, signaling increased insider confidence.

Summary

• IMMUNIC, INC. (IMUX) Director Joerg Neermann acquired a total of 100,000 shares of the company's common stock through open market purchases.
• On June 4, 2025, Mr. Neermann purchased 70,000 shares at a weighted average price of $0.77 per share, with prices ranging from $0.7661 to $0.7730.
• Following the June 4th transaction, his direct beneficial ownership stood at 170,000 shares.
• On June 5, 2025, an additional 30,000 shares were acquired at a price of $0.76 per share.
• After the June 5th transaction, Mr. Neermann's total direct beneficial ownership increased to 200,000 shares.
• Both purchases were made in Euros and converted to U.S. dollars using exchange rates of Euro 1.00 = U.S. dollar 1.1384 on June 4, 2025, and Euro 1.00 = U.S. dollar 1.1477 on June 5, 2025.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director has significantly increased their stake in the company, indicating confidence in its future.

Positives

• A director increasing their stake in the company through open market purchases often signals confidence in the company's future prospects and valuation.
• The acquisition of 100,000 shares by a director represents a notable increase in insider ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider buying, particularly by a director, can be interpreted by the market as a positive signal, suggesting that those closest to the company believe its stock is undervalued or that positive developments are anticipated. This is a common occurrence across various industries, including biotechnology, where IMMUNIC operates.

Related Party Transactions

• The reported stock purchases by Director Joerg Neermann are considered related party transactions, as they involve an insider acquiring company securities.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive indicator of management's belief in the company's value and future performance, potentially boosting investor confidence.

Key Dates

Keywords

IMMUNIC, IMUX, Joerg Neermann, Insider Trading, Stock Purchase, Director, Beneficial Ownership, Form 4, SEC Filing, Equity Acquisition